Frontlight ResearchEarly access
CompletedNo phase
Self-Administered 2-Hour Oral Glucose Tolerance Test
Key facts
- Who runs it
- Prisma Health-Upstate
- Where
- Greenville, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 200 people enrolled
- Started
- 2 Nov 2023
- Ended
- 1 May 2025
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Self-administered oral glucose tolerance test
- Record updated
- 2 July 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Cannot take part
Show the full registry criteria (12)Hide the full registry criteria
Who can take part
- Maternal age 18 years or older
- English or Spanish speaking
- Diagnosis of gestational diabetes with recommendation for postpartum screening, by any of the following criteria (1) HgbA1c 5.9-6.4% at ≤ 14 6/7 weeks, (2) HgbA1c ≥ 5.9% at 15-23 6/7 weeks, (3) 50-gram oral glucose tolerance test plasma glucose value ≥ 200 mg/dL, (4) 2 or more abnormal plasma glucose values on a 100-gram oral glucose tolerance test with the following thresholds: fasting ≥ 95 mg/dL, 1 hour ≥ 180 mg/dL, 2 hour ≥155 mg/dL, 3 hour ≥140 mg/dL or (5) fasting blood glucose ≥ 126
- No personal history of Type 1 or Type 2 diabetes defined by self-reported or documented history, or HgbA1c >/=6.5% at ≤ 14 6/7 weeks gestation
- Antepartum care with Prisma Health affiliated obstetric practices
- Delivery at Greenville Memorial Hospital
- Active Epic MyChart access at time of enrollment
- Capable of providing informed consent
Who cannot take part
- Pre-pregnancy diagnosis of diabetes (Type 1, 2, or other form of diabetes)
- No glucometer or supplies for fingerstick glucose monitoring, or inability to perform fingerstick glucose monitoring
- Unable to provide informed consent
- Inability to follow up for routine postpartum care
Where in United States
- Prisma Health Greenville Memorial HospitalGreenville, United States
About the trial
What the trial wants to find out
The goal of this randomized controlled trial is to evaluate whether self-administered postpartum diabetes screening tests in patients with gestational diabetes improves screening completion rates. The primary question it aims to answer is:
Read full original descriptionShow less
1. Does a self-administered 75-gram oral glucose tolerance test with virtual follow-up visit increase the rate of postpartum diabetes screening within 12 weeks of delivery?
The 2 groups in the trial
- Self-administered diabetes screenTreatment being tested
Self-administered 75-gram oral glucose tolerance test with 4-week virtual follow-up visit. Drug: GlucoCrush
Treatment: Self-administered oral glucose tolerance test
- Routine postpartum careNo study treatment, for comparison
Office based oral glucose tolerance test at 6 weeks postpartum, per normal protocol. Drug: GlucoCrush
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Self-Administered 2-Hour Oral Glucose Tolerance Test: A Randomized Controlled Trial
- Record updated
- 2 July 2025